|
US2014249299A1
|
|
Hybrid polypeptides with selectable properties
|
|
WO2013177565A1
|
|
Insulin-pramlintide compositions and methods for making and using them
|
|
AU2013205769A1
|
|
Exendin for treating diabetes and reducing body weight
|
|
WO2013163162A1
|
|
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US2015133373A1
|
|
Transmucosal delivery of engineered polypeptides
|
|
WO2013148871A1
|
|
Engineered polypeptides
|
|
WO2013059336A1
|
|
Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
|
|
WO2013009545A1
|
|
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
SG194998A1
|
|
Amylin peptides and derivatives and uses thereof
|
|
CA2813038A1
|
|
Highly soluble leptins
|
|
MX2013001131A
|
|
Glp-1 receptor agonist compounds having stabilized regions.
|
|
EP2600887A2
|
|
Microcrystalline y receptor agonists
|
|
EP2416797A2
|
|
Amylin agonist compounds for estrogen-deficient mammals
|
|
AU2007267833A1
|
|
Composition and methods for treatment of congestive heart failure
|
|
AU2007227202A1
|
|
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
RS53814B1
|
|
Exendin for treating diabetes and reducing body weight
|
|
AU2006235183A1
|
|
Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
|
|
AU2005242228A1
|
|
Methods for regulating gastrointestinal motility
|
|
CN103626866A
|
|
Pancreatic polypeptide family motifs, polypeptides comprising the same and method
|
|
AU2005305036A1
|
|
Treatment of obesity and related disorders
|
